Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

October 24, 2018

Sermonix Launches Phase 2 Trial Testing Lasofoxifene in Advanced Breast Cancer Patients with ER Mutations

News

Sermonix is launching a Phase 2 trial to determine if its lead investigational medicine lasofoxifene is better than Faslodex (fulvestrant) at delaying disease progression or death in breast cancer patients ... Read more

May 23, 2017

MCLA-128 Helps Metastatic Breast Cancer Patients, First Results of Phase 1/2 Trial Indicate

News

Merus’ MCLA-128 antibody has helped patients with HER2-positive metastatic breast cancer who failed several lines of HER2 inhibitor therapy, according to initial results of a Phase 1/2 clinical trial. One ... Read more

May 17, 2017May 17, 2017

Phase 2 Trial to Assess EP-101 Cancer Vaccine-Bavencio Combo Therapy in HER2- Breast Cancer Patients

News

EpiThany says it will test its multi-antigen vaccine EP-101 STEMVAC — in combination with the PD-L1 antibody Bavencio (avelumab) — as a neoadjuvant therapy in breast cancer patients, under a three-way ... Read more

May 16, 2017May 16, 2017

Oncolytics’ Reolysin Receives FDA Fast Track Designation for Metastatic Breast Cancer

News

The U.S. Food and Drug Administration has granted fast track status to Reolysin for treating metastatic breast cancer, according to its developer, Oncolytics Biotech. Fast track accelerates the review of ... Read more

May 12, 2017

CapeRay Wins US Patent for Dual-Mode Imaging System to Detect Breast Cancer

News

CapeRay has received a U.S. patent for its dual-mode breast imaging system, which combines X-rays and ultrasounds in a single device. It is the second patent the system has received. The first was ... Read more

May 11, 2017May 11, 2017

FDA Approves Kisqali Femara Co-Pack to Treat Subset of Advanced Breast Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has approved Novartis Oncology‘s Kisqali Femara Co-Pack for to treat postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. The Co-Pack, which includes ... Read more

May 9, 2017

FDA Approves LOCalizer to Help Surgeons Find Breast Cancer Lesions for Removal

News

The U.S. Food and Drug Administration has approved Faxitron‘s LOCalizer to help surgeons locate the breast cancer lesions they will remove. Manufactured by Health Beacons, LOCalizer is a wireless radiofrequency identification ... Read more

May 4, 2017May 4, 2017

Cell Group Thought to Be Cause of Taxane Resistance in Triple Negative Breast Cancer Identified in Mice

News

A study in mice has shown that the mechanism behind taxane resistance in triple-negative breast cancer (TNBC) relies on the expansion of a specific cancer cell population, a CD49f+ population, with tumor-initiating ... Read more

April 28, 2017May 25, 2017

FDA Advisory Committee to Review Puma’s Request for Neratinib Approval

News

A U.S. Food and Drug Administration advisory committee will begin a review on May 24 of Puma Biotechnology‘s neratinib as a breast cancer treatment. If the independent Oncologic Drug Advisory ... Read more

April 27, 2017April 28, 2017

ICAD Displaying its Radiation System for Residual Breast Cancer at Conference

News

ICAD is showcasing its Xoft radiation system for treating post-surgery residual breast cancer at the American Society of Breast Surgeons annual meeting in Las Vegas. Two leading breast-cancer surgeons agreed to ... Read more

Pin It on Pinterest